Cargando…
Switching to Aripiprazole as a Strategy for Weight Reduction: A Meta-Analysis in Patients Suffering from Schizophrenia
Weight gain is one of the major drawbacks associated with the pharmacological treatment of schizophrenia. Existing strategies for the prevention and treatment of obesity amongst these patients are disappointing. Switching the current antipsychotic to another that may favorably affect weight is not y...
Autores principales: | Barak, Yoram, Aizenberg, Dov |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2943136/ https://www.ncbi.nlm.nih.gov/pubmed/20871835 http://dx.doi.org/10.1155/2011/898013 |
Ejemplares similares
-
Clinical and psychosocial remission in schizophrenia: correlations with antipsychotic treatment
por: Barak, Yoram, et al.
Publicado: (2012) -
PM390. Comparison of Fast Versus Slow Strategy in Switching Schizophrenia Patients to Aripiprazole from Other Antipsychotics
por: Hwang, Tzung-Jeng, et al.
Publicado: (2016) -
The effect of switching from oral low-dose aripiprazole to aripiprazole once-monthly 300 mg on the quality of life in three patients with schizophrenia
por: Suzuki, Hidenobu, et al.
Publicado: (2017) -
Aripiprazole for late-life schizophrenia
por: Rado, Jeffrey, et al.
Publicado: (2010) -
Review of depot aripiprazole for schizophrenia
por: Motiwala, Farha Bilal, et al.
Publicado: (2013)